Erlotinib 25/100/150 Mg Adco 25 mg, 100 mg, 150 mg Tablet
PDF Leaflet Revision Date: 10 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced non-small cell lung cancer, bronchial adenocarcinoma, and pancreatic cancer.
Dosage (summary)
150 mg daily for NSCLC and bronchial adenocarcinoma; 100 mg daily for pancreatic cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
- Smokers
Pregnancy & Breastfeeding
Avoid pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Warfarin
- Proton pump inhibitors
Contraindications
- Hypersensitivity to erlotinib
Common side effects
- Rash
- Diarrhoea
- Fatigue
- Anorexia
Counselling Points
- Take on an empty stomach
- Monitor for severe diarrhoea
- Avoid smoking
Serious warnings
- Interstitial lung disease
- Gastrointestinal perforation
- Hepatic failure
Important Disclaimer
The Erlotinib 25/100/150 Mg Adco 25 mg, 100 mg, 150 mg Tablet professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
